New ISPE APQ Guide Helps Companies Improve Change Management Systems
Lori Rae Chelemedos
What is the current state of your organization’s Change Management (CM) System? The effective management of change throughout the product lifecycle enables quality improvement and is critical to patient safety, supply reliability, as well as operational effectiveness and efficiency.
ISPE’s Advancing Pharmaceutical Quality (APQ) program recently launched its latest guide, Change Management System with the objective of helping companies evaluate and optimize their change management system. The APQ program is built on the foundation of ICH Q10.
ICH Q10 [R1] sets a clear expectation that companies required an effective change management system. More specifically, a change management system should assure that changes are phase appropriate, performed in a timely and effective manner, and draft continual improvement.
Pharmaceutical companies are required to have a Change Management System in place, but an inadequate one may result in ineffective changes that require rework or missed opportunities. This Guide focuses on how to evaluate and optimize the system a company has, provides tools that can be used to improve the system, and offers guidance on how to improve and develop a Change Management System that is appropriate to a company’s maturity level.
What are the benefits of having an effective Change Management System?
The Change Management System is the mechanism by which continual improvements are made. With a robust system in place, companies will find changes can be made in a timely and effective manner. For example, should a company identify a deviation trend such as a piece of equipment or material that is routinely failing, an appointed change owner can work across functions to evaluate the issue, seek a robust solution, and implement that solution promptly using a structured approach.
What are the negative impacts of having an ineffective Change Management System?
It is a regulatory requirement to have a Change Management System. However, many companies have not required the cross-functional collaboration that is necessary to adequately evaluate and implement change. As a consequence, this lack of stakeholder and customer input frequently results in rework and/or missed change opportunities due to gaps in the design of the change.
What are the signs that a company’s Change Management System is inadequate?
There are various signs that a company’s Change Management System is inadequate and range from the way in which records are managed, to poor solution design, to oversights during implementation. More specifically, the system may need additional attention if the information recorded in a change record does not contain enough information for a reader to understand the issue and resulting activities and design, and/or if records are continually late or aging for a long period of time, the ‘problem’ that the change was intended to solve reappears, or there were identified areas that failed during implementation (e.g., some stakeholders did not receive training, etc.).
Why should someone purchase this Guide?
This Guide will help leaders in the pharmaceutical industry understand the expectations of a Change Management System and help them gauge the health of their company’s current Change Management System. It provides guidance on how to approach improvements and develop a plan that is appropriate to a company’s maturity level and will help them understand how the Change Management System integrates into other areas of the FDA’s Pharmaceutical Quality System and how those areas interact with the Change Management System.
What are some of the key takeaways from this Guide?
It is very important to understand the expectations and opportunities at every Change Management process maturity level and to continually be evaluating the current maturity of a company’s systems and related continual improvement. This Guide will help people in the pharmaceutical industry understand expectations and identify aspects of change management where potentially a company can improve, and provide the tools to improve their change management system.
The PQLI Change Management guide focuses on what a Change Management System is. The APQ Change Management Guide focuses on how to evaluate and optimize the system that a company has.
About APQ
ISPE’s Advancing Pharmaceutical Quality (APQ) program proposes an industry-led approach to advance pharmaceutical quality beyond the submission of data for harmonized, reportable metrics. The basic framework of the program is to “assess and aspire” quality maturity. The program is aligned with international initiatives that promote quality excellence, as well as with the FDA’s interest in quality management maturity and rating the maturity of manufacturing facilities, as cited in their 2019 Drug Shortages report. The result is a program that organizations can leverage to ensure a continuous supply of quality medicines to patients.
The APQ Guide Series provides a practical set of tools and systematic approaches for organizations to proactively advance the maturity and effectiveness of the following PQS elements:
Corrective and Preventive Action System
Management Responsibilities and Management Review
Change Management System
Process Performance and Product Quality Monitoring System
The ISPE APQ Guide: Management Responsibilities and Management Review focuses specifically on application of the APQ framework to leadership systems.
Lori Chelemedos is the CEO and principal consultant at Pac-Side LLC, a management consulting firm specializing in regulatory compliance, quality systems and business process improvement...
ISPE Women in Pharma®’s dedication to diversity, equity, and Inclusion isn't just about aspirations: it’s about action. Mentor ISPE, launched in 2023 by members for members, is a testament to this commitment. Over the past two years, more than 700 professionals from around the world have joined ISPE on this journey, and as Mentor ISPE approaches its third year, the team invites ISPE...
The 2024 ISPE Annual Meeting & Expo is the pharmaceutical industry’s gateway to discovering the latest trends, technologies, and best practices shaping the future of pharmaceutical engineering. This year, 13-16 October in Orlando, Florida, USA, ISPE has curated a diverse...
Miriam Kremer-van der Kamp is the Business Developer at VILS Switzerland GmbH and an active ISPE member with the ISPE Germany/Austria/Switzerland (DACH) Affiliate, ISPE Women in Pharma, and ISPE Emerging Leaders. In this interview, conducted by Edyna Miguez, Membership Growth Manager at ISPE, Kremer-van der Kamp weighs in on why she joined ISPE, the benefits she’s experienced thus far, and...